|
Time point
|
ISR*
|
FLS*
|
GSE†
|
|---|
|
Week 4 (n = 115)
| | | |
|
Mean (SD)
|
13.2 (4.02)
|
13.4 (4.56)
|
6.8 (3.16)
|
|
Median (range)
|
13 (4-19)
|
13 (6-20)
|
6 (3-15)
|
|
Week 8 (n = 109)
| | | |
|
Mean (SD)
|
13.4 (3.64)
|
12.9 (4.10)
|
7.5 (3.16)
|
|
Median (range)
|
13.5 (6-20)
|
12 (5-20)
|
8 (3-15)
|
|
Week 12 (n = 104)
| | | |
|
Mean (SD)
|
13.1 (3.39)
|
12.2 (4.30)
|
7.6 (3.05)
|
|
Median (range)
|
13 (6-20)
|
11 (5-20)
|
8 (3-15)
|
|
p-value‡
|
0.902
|
0.022
|
0.002
|
- *Range: 1 (mild) to 20 (severe)
-
†Range: 1 (poor treatment satisfaction) to 15 (excellent treatment satisfaction)
-
‡Repeated measures analysis of variance
-
FLS 'flu-like' symptoms, GSE global side effects, ISR injection-site reactions; MSTCQ Multiple Sclerosis Treatment Concern Questionnaire, SD standard deviation
